Stocks Health care PTCT
NASDAQ · Health carePtc Therapeutics, Inc. (PTCT)
Ptc Therapeutics, Inc. brought in $1.2B of revenue over the twelve months to September 30, 2026, down 35.1% from a year earlier. It posted a net loss of $106M. Operating cash flow minus capital spending left $702.3M of free cash flow in fiscal 2025. At September 30, 2026 it held $508.9M in cash against $536.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on October 29, 2026.
Key facts about Ptc Therapeutics, Inc.
- Net worth
- Ptc Therapeutics, Inc. has a market value (market cap) of $5.4B at the latest share price, and shareholders' equity of -$191.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.7B (+114.5% year on year), with net income of $682.6M. Over the 12 months to September 30, 2026: revenue $1.2B, net loss $106M.
- Cash flow
- In fiscal 2025 operations brought in $711.2M of cash; after $8.9M of capital spending, free cash flow was $702.3M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on October 29, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Ptc Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Ptc Therapeutics, Inc. does
Ptc Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PTCT.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.7B | $682.6M | $7.78 | $702.3M |
| 2024 | $806.8M | -$363.3M | -$4.73 | -$114.2M |
| 2023 | $937.8M | -$626.6M | -$8.37 | -$186.9M |
| 2022 | $698.8M | -$559M | -$7.79 | -$388.7M |
| 2021 | $538.6M | -$523.9M | -$7.43 | -$279.5M |
| 2020 | $380.8M | -$438.2M | -$6.64 | -$211.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where PTCT ranks in Health care
Latest SEC filings
What Ptc Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026
- October 29, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 70% to $357.8M versus the same quarter last year; diluted EPS -$0.62 versus $0.20.
- October 29, 2026
- September 21, 2026
- August 28, 2026
- August 13, 2026
- July 30, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 102% to $360.5M versus the same quarter last year; diluted EPS $0.92 versus -$0.83.
- July 30, 2026
- June 18, 2026
- June 16, 2026Other event 8-K
What is PTCT worth? A DCF from its reported cash flow
Insider trades
What the people running Ptc Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $7.8M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 14, 2026 | Schmertzler MichaelDirector | Soldpre-planned (10b5-1), indirect | 2,118 | $126.1K |
| October 14, 2026 | Schmertzler MichaelDirector | Soldpre-planned (10b5-1), indirect | 382 | $23K |
| October 9, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Exercised options | 192 | $7.6K |
| October 9, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Soldpre-planned (10b5-1) | 192 | $12.3K |
| October 7, 2026 | Schmertzler MichaelDirector | Soldpre-planned (10b5-1), indirect | 2,447 | $155.1K |
| October 7, 2026 | Schmertzler MichaelDirector | Soldpre-planned (10b5-1), indirect | 53 | $3.4K |
| October 6, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Exercised options | 435 | $17.1K |
| October 6, 2026 | Boulding Mark ElliottEXEC. VP AND CLO | Soldpre-planned (10b5-1) | 435 | $27.9K |
Who owns PTCT
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Janus Henderson Group PLC13G, passive | 8.7% | May 15, 2026 |
| Vanguard Portfolio Management13G, passive | 5.88% | April 29, 2026 |
| Vanguard Capital Management13G, passive | 5.17% | April 30, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 382 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 13,964,554 | +1,015,837 |
| Rtw Investments, LP | 7,746,415 | 0 |
| Jupiter Topco LLC | 7,236,402 | new |
| Vanguard Portfolio Management LLC | 4,928,111 | +123,517 |
| State Street Corp | 4,598,952 | +252,433 |
| Wellington Management Group Llp | 4,128,273 | +185,663 |
| Vanguard Capital Management LLC | 3,739,127 | +62,871 |
| Geode Capital Management, LLC | 2,207,376 | -2,578 |
| Toronto Dominion Bank | 2,165,846 | -860,117 |
| Westfield Capital Management Co LP | 1,956,156 | new |
| Hood River Capital Management LLC | 1,738,613 | +74,054 |
| William Blair Investment Management, LLC | 1,722,688 | new |
| D. E. Shaw & Co., Inc. | 1,548,919 | -91,462 |
| Tang Capital Management LLC | 1,500,000 | 0 |
| Bank of America Corp | 1,452,277 | -434,564 |
| Driehaus Capital Management LLC | 1,440,107 | +424,335 |
| Fmr LLC | 1,398,261 | -130,101 |
| Jefferies Financial Group Inc. | 1,357,042 | +2,583 |
| Fuller & Thaler Asset Management, Inc. | 1,156,819 | new |
| Pictet Asset Management Holding SA | 1,147,844 | -35,876 |
Insiders
18 insiders reported holding 2,522,453 shares in total, about $161.8M at the last price.
| Holder | Shares |
|---|---|
| Schmertzler MichaelDirector | 1,454,8601,291,594 held indirectly |
| Klein Matthew B.CHIEF EXECUTIVE OFFICER, Director | 383,868 |
| Boulding Mark ElliottEXEC. VP AND CLO | 105,272 |
| Gravier PierreCHIEF FINANCIAL OFFICER | 83,986 |
| Golden Lee ScottEVP & CHIEF MEDICAL OFFICER | 79,115 |
| Pauwels EricCHIEF BUSINESS OFFICER | 73,411 |
| Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER | 70,199 |
| Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER | 63,0362,737 held indirectly |
| Sollie-Zetlmayer Hege ElisabethDirector | 52,526 |
| Steele Glenn Jr Md PhdDirector | 22,500 |
Questions about PTCT
What does Ptc Therapeutics, Inc. do?
Ptc Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as PTCT. Its shares trade on NASDAQ under the ticker PTCT.
What is Ptc Therapeutics, Inc.'s net worth?
Ptc Therapeutics, Inc. has a market value (market cap) of $5.4B at the latest share price, and shareholders' equity of -$191.2M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Ptc Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $106M on revenue of $1.2B.
How much revenue does Ptc Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Ptc Therapeutics, Inc. reported revenue of $1.2B. That is 35.1% less than a year earlier.
When did Ptc Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on October 29, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the investor disclosure from November 3, 2026.
When is Ptc Therapeutics, Inc.'s next earnings report?
Ptc Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PTCT with
Follow PTCT
Get an email when Ptc Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Ptc Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.